This is a preview of subscription content, log in via an institution to check access.
Notes
2017 euros
Reference
Agirrezabal I, et al. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data. European Journal of Health Economics : 31 Oct 2019. Available from: URL: https://doi.org/10.1007/s10198-019-01122-6
Rights and permissions
About this article
Cite this article
Cost effectiveness of carfilzomib combination therapy. PharmacoEcon Outcomes News 841, 9 (2019). https://doi.org/10.1007/s40274-019-6361-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6361-0